Medtronic is growing its patient monitoring offerings in a partnership with wearable monitor maker BioIntelliSense.
Medtronic said on Wednesday that it now has exclusive distribution rights for the BioButton wearable device for continuous, connected monitoring in U.S. hospitals and 30-day post-acute hospital to home care. The terms of the deal weren’t disclosed.
Golden, Colorado-based BioIntelliSense specializes in remote patient monitoring and analysis of the data captured by its devices.
The BioButton can be collect up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, and heart rate at rest, according to the statement. The device can also be used to monitor patients as they transition from higher acuity to lower acuity healthcare settings.
Medtronic said that when coupled with advanced analytics, the device has the potential to help clinicians better detect early signs of patient deterioration or identify stable patients who may be candidates for an earlier hospital discharge.
The device further builds out Medtronic’s patient monitoring business. The company said that growing patient monitoring offerings can help alleviate pressure from healthcare staffing shortages, which have been a continuing issue for the hospital and medical device industries. Staffing shortages can limit the number of procedures done at a facility and increase the workloads for employees.
"Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before," Frank Chan, president of the company’s patient monitoring business, said in the statement.
Revenue for Medtronic’s patient monitoring unit rose by low-single digits in the company’s first quarter of its fiscal year 2023, according to an August earnings release.
